These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 4570211

  • 1. [Hypolipemic effects of 1-10(hydroxy-2 ethylthio) decane (LL1558), based on 77 cases of essential hyperlipidemia].
    Rouffy J, Loeper J.
    Therapie; 1972; 27(3):433-44. PubMed ID: 4570211
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Reduction of serum lipids in familial hyperlipidemias by a tetralin derivative.
    Oriente P, Motolese M, Cerqua R, Mancini M.
    Int Z Klin Pharmakol Ther Toxikol; 1969 Oct; 2(4):348-53. PubMed ID: 4903988
    [No Abstract] [Full Text] [Related]

  • 4. Antilipidemic drugs. Part 6: LF 178 in man. A preliminary note on a multicenter investigation bearing on 393 subjects with pure or mixed forms of hyperlipidemia.
    Wülfert B, Majoie B, de Ceaurriz A.
    Arzneimittelforschung; 1976 Oct; 26(5):906-9. PubMed ID: 183789
    [Abstract] [Full Text] [Related]

  • 5. [Clinical experimentation of clofibride. Apropos of 40 cases].
    Warembourg H, Jaillard J.
    Lille Med; 1973 Dec; 18(10 Suppl 5):suppl 5:1292-6. PubMed ID: 4802928
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Effects on the serum lipids of bis (hydroxy-2 ethylthio) 1,10 decane (LL 1558) and clofibrate, based on 91 cases of primary hyperlipoproteinemia].
    Rouffy J.
    Sem Hop Ther; 1973 Jan; 49(1):31-6. PubMed ID: 4712022
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical and biological study of a new vascular protective agent and hypolipemic agent, pyridoxine para-chloro-phénoxy-isobutyrate. (Claresan)].
    Fourrier A, Mouton Y.
    Lille Med; 1974 Apr; 19(4 Suppl 11):532-7. PubMed ID: 4612283
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [A double-blind cross-over trial of a new hypolipidaemic drug (author's transl)].
    Proto C, Quadri A, Ratti S, Levi GF, Prandini BD.
    G Ital Cardiol; 1978 Apr; 8(7):743-51. PubMed ID: 355033
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
    Wolfram G, Keller C, Kilani C, Zöllner N.
    Verh Dtsch Ges Inn Med; 1973 Apr; 79():1291-3. PubMed ID: 4597609
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [The clinical use of bis-(hydroxy-ethyl-thio)-1,10-decane in the treatment of hyperlipemic and dyslipemic conditions].
    Vailati G, Montini M, Simonutti M, Nosari I, Pagani G.
    Clin Ter; 1978 May 31; 85(4):361-73. PubMed ID: 668273
    [No Abstract] [Full Text] [Related]

  • 17. [Drug therapy of dyslipidemias].
    Fonda M, Cattin L, Guarnieri G.
    Recenti Prog Med; 2000 May 31; 91(7-8):375-8. PubMed ID: 10932924
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
    McCrindle BW, Ose L, Marais AD.
    J Pediatr; 2003 Jul 31; 143(1):74-80. PubMed ID: 12915827
    [Abstract] [Full Text] [Related]

  • 20. [Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia].
    Colombo L, Monarca A, Goldberg D, Zanetta R.
    Clin Ter; 1979 Oct 31; 91(2):155-71. PubMed ID: 540479
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.